GLYCOMIMETICS INC (GLYC)
US38000Q1022 - Common Stock
We assign a fundamental rating of 2 out of 10 to GLYC. GLYC was compared to 561 industry peers in the Biotechnology industry. GLYC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLYC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GLYC had negative earnings in the past year.
In the past year GLYC has reported a negative cash flow from operations.
GLYC had negative earnings in each of the past 5 years.
In the past 5 years GLYC always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -81.42%, GLYC is not doing good in the industry: 70.09% of the companies in the same industry are doing better.
GLYC has a Return On Equity (-96.05%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.42% | ||
| ROE | -96.05% | ||
| ROIC | N/A |
ROA(3y)-79.61%
ROA(5y)-61.8%
ROE(3y)-94.21%
ROE(5y)-71.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GLYC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
GLYC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GLYC has been increased compared to 5 years ago.
GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
GLYC has an Altman-Z score of -14.43. This is a bad value and indicates that GLYC is not financially healthy and even has some risk of bankruptcy.
GLYC's Altman-Z score of -14.43 is on the low side compared to the rest of the industry. GLYC is outperformed by 82.34% of its industry peers.
GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.43 |
ROIC/WACCN/A
WACC10.63%
2.3 Liquidity
A Current Ratio of 6.41 indicates that GLYC has no problem at all paying its short term obligations.
The Current ratio of GLYC (6.41) is better than 64.14% of its industry peers.
GLYC has a Quick Ratio of 6.41. This indicates that GLYC is financially healthy and has no problem in meeting its short term obligations.
GLYC's Quick ratio of 6.41 is fine compared to the rest of the industry. GLYC outperforms 64.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.41 | ||
| Quick Ratio | 6.41 |
3. Growth
3.1 Past
GLYC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.15%.
GLYC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.
Measured over the past years, GLYC shows a very negative growth in Revenue. The Revenue has been decreasing by -90.05% on average per year.
EPS 1Y (TTM)6.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.08%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
GLYC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.89% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y11.13%
EPS Next 3Y3.33%
EPS Next 5Y11.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
GLYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLYC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.13%
EPS Next 3Y3.33%
5. Dividend
5.1 Amount
No dividends for GLYC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GLYCOMIMETICS INC
NASDAQ:GLYC (1/6/2025, 6:34:46 PM)
After market: 0.2857 +0.01 (+2.04%)0.28
+0 (+1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners35.73%
Inst Owner Change0%
Ins Owners8.32%
Ins Owner Change-8.4%
Market Cap18.05M
Analysts85.71
Price Target1.02 (264.29%)
Short Float %3.57%
Short Ratio0.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.12%
Min EPS beat(2)4.24%
Max EPS beat(2)10%
EPS beat(4)4
Avg EPS beat(4)11.18%
Min EPS beat(4)0%
Max EPS beat(4)30.48%
EPS beat(8)7
Avg EPS beat(8)12.23%
EPS beat(12)10
Avg EPS beat(12)10.12%
EPS beat(16)14
Avg EPS beat(16)12.29%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1805.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.47 | ||
| P/tB | 0.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.42% | ||
| ROE | -96.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-79.61%
ROA(5y)-61.8%
ROE(3y)-94.21%
ROE(5y)-71.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.95% | ||
| Cap/Sales | 213.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.41 | ||
| Quick Ratio | 6.41 | ||
| Altman-Z | -14.43 |
F-Score4
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)18.63%
Cap/Depr(5y)26.36%
Cap/Sales(3y)104.92%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.08%
EPS Next Y-6.84%
EPS Next 2Y11.13%
EPS Next 3Y3.33%
EPS Next 5Y11.89%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.92%
OCF growth 3YN/A
OCF growth 5YN/A